West Pharmaceutical Services Appoints Eric Resnick To Chief Technology Officer

EXTON, Pa., March 1, 2016 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced Eric Resnick has been appointed to serve as Vice President and Chief Technology Officer, succeeding John Paproski, who plans to retire on April 1, 2016. Mr. Resnick will be responsible for leading the Company's Innovation and Technology Team, which has been established to create the next generation of products, from innovation to the commercial stage, across the packaging, containment and delivery product areas.

West logo.
"John Paproski will retire from West with more than 36 years of dedicated service and a legacy of innovative products and services he helped to create and deliver to customers and, ultimately, to patients around the world," said Eric M. Green, President and CEO, West. "A consummate leader and trusted colleague, we celebrate John's contributions to West and his lasting impact, and wish him well in his retirement."

"I leave West with the knowledge that the Company is embarking on a growth journey I have been thrilled to be a part of, and with pride as Eric Resnick, who has served as a critical leader on my team, takes over the reins as Chief Technology Officer," said John Paproski. "I have enjoyed my time at West immensely and look forward to watching the Company continue to grow and evolve as I pursue retirement."

"Over the past 15 years, Eric Resnick has been a pivotal leader within West. His work to bring the SmartDose® electronic wearable injector from concept to commercialization is among many of his accomplishments," continued Mr. Green. "Eric is a well-respected and proven leader at West who will bring valuable skills and experience to the West leadership team. I am confident he will further the great work that has been done to bring innovative, new products to market."

Eric Resnick most recently served as Vice President and General Manager of Integrated Packaging and Delivery within the Innovation and Technology Team. Since January 2010, Mr. Resnick served in various R&D and Engineering executive roles at West, including Vice President R&D and Self-Injection Systems. He also served as Vice President and General Manager of West's Contract Manufacturing Delivery Devices division. Prior to joining West, Mr. Resnick held engineering and operating roles with Eastman Kodak and Ortho Clinical Diagnostics. He is a certified Six Sigma Black Belt with a BS in Plastics Engineering from the University of Massachusetts Lowell and an MBA from the University of Phoenix.

"It's an exciting time to be at West, as our Innovation and Technology Team continues to develop new and enhanced product offerings to meet the ever-growing needs of our pharmaceutical and biotech customers," said Eric Resnick. "We have a strong, motivated team, and I look forward to continuing the good work that our team has started in getting closer to both our customers and the patients who will benefit from our new products."

About West
West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2015 sales of $1.4 billion reflect the daily use of approximately 110 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.

West and the diamond logo are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.

SmartDose® is a registered trademark of Medimop Medical Projects Ltd., a subsidiary of West Pharmaceutical Services, Inc. West seeks partners for its SmartDose electronic wearable injector technology platform. This platform is intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.

Media Contact:
Emily Denney
Global Communications, West Pharmaceutical Services
+ 1-610-594-3035
[email protected]

Suggested Articles

Novartis is ending early discovery at its R&D site in Shanghai to “rebalance” its discovery and early development efforts.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year.